Publications

• Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.

  (Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM.) Am J Hematol. 2022 Jul;97(7):E232-E235 PMID: 35338673 SCOPUS ID: 2-s2.0-85127372897 03/27/2022

• Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

  (Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ.) Blood. 2022 Jun 09;139(23):3366-3375 PMID: 35081255 SCOPUS ID: 2-s2.0-85129375801 01/27/2022

• Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.

  (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE.) J Natl Cancer Inst. 2022 01 11;114(1):160-164 PMID: 34491344 PMCID: PMC8755495 SCOPUS ID: 2-s2.0-85123645552 09/08/2021

• Treatment-Free Remission: the New Goal in CML Therapy.

  (Atallah E, Sweet K.) Curr Hematol Malig Rep. 2021 10;16(5):433-439 PMID: 34618317 PMCID: PMC8495665 SCOPUS ID: 2-s2.0-85116717959 10/08/2021

• Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.

  (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplant. 2021 08;56(8):1998-2004 PMID: 33824440 SCOPUS ID: 2-s2.0-85103674051 04/08/2021

• Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.

  (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V.) Leuk Lymphoma. 2021 07;62(7):1730-1739 PMID: 33648418 SCOPUS ID: 2-s2.0-85110241807 03/03/2021

• Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?

  (Badar T, Atallah E.) Expert Opin Investig Drugs. 2021 Jun;30(6):665-673 PMID: 33836635 SCOPUS ID: 2-s2.0-85104939879 04/11/2021

• Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.

  (Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E.) Cancer. 2021 04 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020

• Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making.

  (Atallah EL.) Best Pract Res Clin Haematol. 2021 03;34(1):101240 PMID: 33762095 SCOPUS ID: 2-s2.0-85100148584 03/26/2021

• Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

  (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E.) Bone Marrow Transplantation. August 2021;56(8):1998-2004 SCOPUS ID: 2-s2.0-85103674051 08/01/2021

• Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making

  (Atallah EL.) Best Practice and Research: Clinical Haematology. March 2021;34(1) SCOPUS ID: 2-s2.0-85100148584 03/01/2021

• Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.

  (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE.) JAMA Oncol. 2021 Jan 01;7(1):42-50 PMID: 33180106 PMCID: PMC7662490 SCOPUS ID: 2-s2.0-85096163350 11/13/2020